Atria Investments Inc Buys 4,511 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Atria Investments Inc raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 24.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,099 shares of the company’s stock after purchasing an additional 4,511 shares during the quarter. Atria Investments Inc’s holdings in Intellia Therapeutics were worth $475,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in NTLA. Blue Trust Inc. increased its holdings in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after buying an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank bought a new position in Intellia Therapeutics during the third quarter worth about $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics during the third quarter worth approximately $54,000. Finally, First Horizon Advisors Inc. raised its stake in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after buying an additional 472 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Ratings Changes

NTLA has been the topic of a number of recent analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a report on Tuesday. Chardan Capital increased their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research report on Monday. Citigroup reduced their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. lowered their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Finally, Oppenheimer lowered their target price on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.94.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.20% of the stock is owned by corporate insiders.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $13.12 on Thursday. Intellia Therapeutics, Inc. has a 52-week low of $12.82 and a 52-week high of $34.87. The company has a market capitalization of $1.34 billion, a PE ratio of -2.40 and a beta of 1.81. The company has a fifty day moving average of $18.40 and a 200-day moving average of $21.91.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same period in the previous year, the company earned ($1.38) EPS. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.13 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.